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REPLY
We thank Drs. Bahl and Chongtham for their interest in our study
on the effects of atorvastatin on systolic function and markers of
inflammation in patients with nonischemic heart failure (HF) (1).
We agree with them that nonischemic HF represents a heteroge-
neous condition with various etiologies. The authors correctly
point out that duration of illness is an important determinant in
response to therapy in patients with nonischemic HF. Patients
with newly diagnosed nonischemic HF, for example, may have
myocarditis with transient left ventricular (LV) systolic function
followed by a spontaneous improvement in ventricular function,
regardless of medical therapy.
We disagree, however, that patients in this trial should have
been randomized according to duration of illness. The inclusion
criteria for this study required that patients on stable HF medica-
tions for at least three months before study entry, effectively
excluding patients with more transient forms of nonischemic HF
that may be likely to resolve spontaneously. Moreover, we believe
that other factors play a much more important role in determining
response to therapy and long-term prognosis in these patients. For
example, Felker et al. (2) followed 1,230 patients with nonischemic
HF for an average of 4.4 years and found that older age, male
gender, and etiology of HF were associated with increased mor-
tality. Other teams have demonstrated that prognosis in this group
of patients is primarily determined by age, LV ejection fraction,
and symptomatic HF (3,4).
In conclusion, our study demonstrated that therapy with ator-
vastatin improved LV systolic function and markers of inflamma-
tion in patients with chronic forms of nonischemic HF—results
that we believe were relatively unbiased by duration of illness.
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Beta-Blockers and Exercise
In a recent issue of JACC, Kokkinos et al. (1), after evaluating the
role of beta-blockers at mitigating exercise-induced blood pres-
sure (BP) rise in hypertensive men, concluded that “for patients
engaging in vigorous activities such as snow-shoveling, basketball,
tennis, racquetball, and so on, beta-blockade–based therapy can
protect against excessive and repetitive elevations in BP which may
occur during such activities.”
Earlier studies have shown that beta-blockers bring about a clear
reduction in exercise endurance in young healthy subjects (2,3) and
trained sportsmen (4,5). Similarly, in patients with hypertension
who are on beta-blockers, the reduction in exercise tolerance in
part could be attributable to be secondary to these drugs (6). In the
study by Kokkinos et al. (1), both the exercise duration and the
total metabolic equivalents achieved were significantly lower in the
group on beta-blockers compared to other medications. In the
ASCOT–BPLA (Anglo-Scandinavian Cardiac Outcome Trial–
Blood Pressure Lowering Arm) study of 19,257 patients with
hypertension and at least three other coronary risk factors but no
coronary artery disease, atenolol-based treatment resulted in a 14%
higher risk of coronary events and a 23% increase in stroke rate
compared to amlodipine-based regimen (7). In a recent meta-
analysis of 134,000 patients on antihypertensive therapy, beta-
blocker treatment was associated with a 16% higher incidence of
stroke compared to other antihypertensive treatments (8). Of note,
beta-blockers have recently been shown to differ in their effect on
central aortic BP compared to peripheral brachial pressure. The
Conduit Artery Functional Endpoint (CAFÉ trial) and other
studies have documented that beta-blockers have a lesser effect on
central systolic pressure than do angiotensin-converting enzyme
(ACE) inhibitors, diuretics, and calcium antagonists (9–11). In
fact, results of the CAFÉ (12) study show that a calcium
antagonist–based treatment is much more effective at reducing
central aortic BP than is a conventional atenolol-based (beta-
blocker) regimen. Importantly, the study also suggests that the
central aortic BP may be more predictive of cardiovascular events,
such as stroke and myocardial infarction, than traditional periph-
eral (brachial) BP measurements (12).
We believe, therefore, that a conclusion, such as the above,
based on peripheral BP measurements may be inappropriate. For
hypertensive patients engaging in “vigorous activities,” we do need
a medication that curtails their (central) BP rise but not one that
curtails their activity.
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REPLY
We appreciate Drs. Bangalore and Messerli’s interest in our study
(1). In their letter to the editor they argue that our statement—“for
patients engaging in vigorous activities . . . -blockade-based ther-
apy can protect against excessive and repetitive elevations in blood
pressure (BP) which may occur during such activities”—may be
inappropriate because it is based on peripheral BP measurements.
They present evidence for greater risk of cardiovascular events or
lower-risk reduction with beta-blockers versus other antihyperten-
sive agents (2–4) and they suggest that this lower risk is due to
lower central BP achieved by antihypertensive agents other than
beta-blockers, as supported by the 4.3-mm Hg lower central BP
reported in the CAFÉ trial (4). Finally, they suggest that for
hypertensive patients “we do need a medication that curtails their
(central) BP rise but not one that curtails their activity.”
We agree that beta-blockers are not as effective in reducing
stroke rates when compared to other antihypertensive agents.
However, it is important to point out that there are no data on
therapies and outcomes in hypertensive patients with an exagger-
ated BP response to exercise.
Our statement is based on observations that the exercise BP on
those treated with beta-blockers was 14–19 mm Hg lower at
different workloads and for different antihypertensive agents. Most
will agree that the relationship between central and peripheral BP
is direct, and a change in one (central or peripheral) will result in
a proportional change in the same direction on the other. There-
fore, it is reasonable to assume that a peripheral exercise BP that is
14–19 mm Hg lower than the BP of those treated with antihy-
pertensive agents other than beta-blockers is more likely to reflect
a proportionally lower than higher central BP.
We also agree that beta-blockers reduce exercise time. The peak
exercise time in our patients on beta-blocker-based therapy was
lower by 19 s compared to the other agents. However, we are
confident that most health care providers and patients will gladly
trade 19-s reduction in peak exercise time for 19-mm Hg lower
systolic BP during physical activities.
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Standard Deviation of Sequential Five-
Minute R-R Interval Means (SDANN)
Is a Prognostic Marker, but Not
Necessarily an Autonomic Marker
The recent study by Fantoni et al. (1) provides strong data that
standard deviation of sequential 5-minute R-R interval means
(SDANN, a long-term measure of heart rate variability [HRV]) is
an important clinical tool. The researchers have convincingly
shown that 1) successful cardiac resynchronization therapy (CRT)
improved SDANN and 2) that an early improvement in SDANN
predicted a favorable long-term outcome.
The investigators interpret this increase in SDANN as reflecting
changes in autonomic tone, specifically modifications of the sympa-
thetic nervous system and parasympathetic nervous system interac-
tions in the heart. Although we agree that short-term measures of
HRV such as high-frequency (0.15 to 0.4 Hz) and low-frequency
(0.04 to 0.15 Hz) variability have been shown to be modulated by the
autonomic nervous system, there are no data showing that SDANN
is a reflection of the autonomic nervous system.
In contrast, we have shown that SDANN is heavily influenced by
physical activity. In an earlier study, the largest contributions to the
SDANN came around the transitions going into and waking from
sleep (2). We have also shown in both patients with heart failure and
in healthy subjects that SDANN significantly increased by changing
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